According to Nanjing Xinbai's announcement, net profit for the first half of 2026 is expected to be 35.1202 million yuan to 38.469 million yuan, a year-on-year decrease of 77.15% to 78.90%. During the reporting period, sales of PROVENGE products of Dendreon Pharmaceuticals LLC controlled by Dendreon Pharmaceuticals LLC, a wholly-owned subsidiary of the company, declined, reducing Shiding Hong Kong's net profit by about 142 million yuan.

According to Nanjing Xinbai's announcement, net profit for the first half of 2026 is expected to be 35.1202 million yuan to 38.469 million yuan, a year-on-year decrease of 77.15% to 78.90%. During the reporting period, sales of PROVENGE products of Dendreon Pharmaceuticals LLC controlled by Dendreon Pharmaceuticals LLC, a wholly-owned subsidiary of the company, declined, reducing Shiding Hong Kong's net profit by about 142 million yuan.